<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937235</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA023507</org_study_id>
    <secondary_id>R01DA023507</secondary_id>
    <nct_id>NCT00937235</nct_id>
  </id_info>
  <brief_title>Treatment of Smoking Among Individuals With PTSD</brief_title>
  <official_title>Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effect of combining prolonged exposure, a cognitive-behavioral
      treatment program for post-traumatic stress disorder (PTSD) with medication (varenicline) and
      counseling treatments for smoking cessation. Subjects will be randomly assigned to a 3-month
      treatment of either: 1) varenicline and smoking cessation counseling alone, or 2) prolonged
      exposure, varenicline, and smoking cessation counseling. Assessments will be completed at the
      end of treatment and 6-month follow-up.

      We hypothesize that, at the end of treatment and at follow-up, abstinence rates and decrease
      in cigarettes smoked will be greater among participants who receive the combined treatment
      for both PTSD and smoking.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Smoking Abstinence</measure>
    <time_frame>At 3-month follow-up (6-month post-quit day)</time_frame>
    <description>Number of participants reporting seven-day point prevalence abstinence (PPA), which was defined as self-reported abstinence for 7 days prior to the assessment, serum cotinine level of &lt;15ng/ml, and CO &lt; 10 ppm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Serum Cotinine</measure>
    <time_frame>At end of 3-month follow-up</time_frame>
    <description>Level of cotinine in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Symptom Scale Interview (PSS-I) at Post-Treatment</measure>
    <time_frame>Post-treatment, occurring 12 weeks after the start of treatment (week 0)</time_frame>
    <description>Posttraumatic Symptom Scale Interview at post-treatment assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Symptom Scale Interview (PSS-I) Total Score at 3-Month Follow-Up</measure>
    <time_frame>3-month follow-up</time_frame>
    <description>Posttraumatic Symptom Scale Interview at 3-month follow-up assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale (HAM-D) Total Score at Post-Treatment</measure>
    <time_frame>Post-Treatment assessment, occurring 12 weeks after the start of treatment (week 0)</time_frame>
    <description>Hamilton Depression scale (HAM-D) at post-treatment assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale (HAM-D) Total Score at 3-Month Follow-Up</measure>
    <time_frame>3-month follow-up</time_frame>
    <description>Hamilton Depression scale (HAM-D) at 3-month followup assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLFB - Total Cigarettes Smoked Week Before Appointment (at Post-Treatment)</measure>
    <time_frame>Week before Post-Treatment visit occurring at week 12, i.e. number of cigarettes smoked for the week prior to this week 12 visit</time_frame>
    <description>Timeline Followback - Total number of cigarettes smoked the week before Post-Treatment visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLFB - Cigarettes Smoked Week Before 3-Month Follow-up</measure>
    <time_frame>3-month follow-up</time_frame>
    <description>Timeline followback - Number of cigarettes smoked the week before 3-month follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Cigarette Smoking</condition>
  <condition>Nicotine Dependence</condition>
  <condition>Post-traumatic Stress Disorder</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Integrated Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prolonged Exposure + Varenicline + Medication Management Counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline + Medication Management Counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>1 mg tablets, orally, twice daily x 12 weeks</description>
    <arm_group_label>Integrated Treatment</arm_group_label>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medication Management Counseling</intervention_name>
    <description>15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
    <arm_group_label>Integrated Treatment</arm_group_label>
    <arm_group_label>Varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Exposure</intervention_name>
    <description>75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
    <arm_group_label>Integrated Treatment</arm_group_label>
    <other_name>Cognitive-Behavioral Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female treatment-seeking cigarette smokers between 18-75 years old who smoke
             an average of â‰¥10 cigarettes/day during past year;

          -  Current diagnosis of chronic PTSD (symptom duration &gt; 3 months) with clinically
             significant trauma-related symptoms (PSS-I &gt;= 20)

          -  Live a commutable distance to the University of Pennsylvania and agree to follow-up
             visits;

          -  Agree not to use other forms of smoking cessation treatment or treatment for PTSD
             during the study period;

          -  If taking SRIs or other medications at intake, have been on stable medication and dose
             regimen for past 3 months and agree to maintain current regimen if possible;

          -  Demonstrate the capacity to provide informed consent;

          -  Speak and read English.

        Exclusion Criteria:

          -  History of drug or alcohol abuse or dependence in past 3 months or any unwillingness
             to not smoke marijuana during the first 13 weeks of the study;

          -  Current and continuing intimate relationship with a physically or sexually abusive
             partner;

          -  Current suicidal ideation with intent and/or plan that, in the judgment of the
             investigator, should be the focus of treatment;

          -  Prior serious suicide attempt, as judged by the evaluator to have a high degree of
             lethality;

          -  Current or past history of psychosis (bipolar disorder or schizophrenia);

          -  History of significant cardiovascular disease or uncontrolled hypertension in past 6
             months;

          -  Women who are pregnant, likely to become pregnant (i.e., sexually active and not using
             contraception), or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edna B Foa, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine, Dept of Psychiatry, Center for Treatment and Study of Anxiety</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.upenn.edu/ctsa/</url>
    <description>Center for the Treatment and Study of Anxiety</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2017</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Behavior Therapy</keyword>
  <keyword>Varenicline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through advertisements and referrals to the University of Pennsylvaniaâ€™s Center for the Treatment and Study of Anxiety (CTSA), Transdisciplinary Tobacco Use Research Center (TTURC), and the Philadelphia VA Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Integrated Treatment</title>
          <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
        </group>
        <group group_id="P2">
          <title>Varenicline</title>
          <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Integrated Treatment</title>
          <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
        </group>
        <group group_id="B2">
          <title>Varenicline</title>
          <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="9.7"/>
                    <measurement group_id="B2" value="42.6" spread="10.2"/>
                    <measurement group_id="B3" value="42.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 7-day Point Prevalence Smoking Abstinence</title>
        <description>Number of participants reporting seven-day point prevalence abstinence (PPA), which was defined as self-reported abstinence for 7 days prior to the assessment, serum cotinine level of &lt;15ng/ml, and CO &lt; 10 ppm.</description>
        <time_frame>At 3-month follow-up (6-month post-quit day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Smoking Abstinence</title>
          <description>Number of participants reporting seven-day point prevalence abstinence (PPA), which was defined as self-reported abstinence for 7 days prior to the assessment, serum cotinine level of &lt;15ng/ml, and CO &lt; 10 ppm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Serum Cotinine</title>
        <description>Level of cotinine in blood</description>
        <time_frame>At end of 3-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Serum Cotinine</title>
          <description>Level of cotinine in blood</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.0" spread="119.4"/>
                    <measurement group_id="O2" value="149.2" spread="149.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Posttraumatic Symptom Scale Interview (PSS-I) at Post-Treatment</title>
        <description>Posttraumatic Symptom Scale Interview at post-treatment assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
        <time_frame>Post-treatment, occurring 12 weeks after the start of treatment (week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Posttraumatic Symptom Scale Interview (PSS-I) at Post-Treatment</title>
          <description>Posttraumatic Symptom Scale Interview at post-treatment assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.19" spread="10.63"/>
                    <measurement group_id="O2" value="18.84" spread="11.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Posttraumatic Symptom Scale Interview (PSS-I) Total Score at 3-Month Follow-Up</title>
        <description>Posttraumatic Symptom Scale Interview at 3-month follow-up assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
        <time_frame>3-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Posttraumatic Symptom Scale Interview (PSS-I) Total Score at 3-Month Follow-Up</title>
          <description>Posttraumatic Symptom Scale Interview at 3-month follow-up assessment, which measures severity of post-traumatic stress disorder (PTSD) symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 51.
Higher scores indicate higher/worse levels of PTSD.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.35" spread="11.73"/>
                    <measurement group_id="O2" value="16.74" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Scale (HAM-D) Total Score at Post-Treatment</title>
        <description>Hamilton Depression scale (HAM-D) at post-treatment assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
        <time_frame>Post-Treatment assessment, occurring 12 weeks after the start of treatment (week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Scale (HAM-D) Total Score at Post-Treatment</title>
          <description>Hamilton Depression scale (HAM-D) at post-treatment assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="6.00"/>
                    <measurement group_id="O2" value="11.84" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Scale (HAM-D) Total Score at 3-Month Follow-Up</title>
        <description>Hamilton Depression scale (HAM-D) at 3-month followup assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
        <time_frame>3-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Scale (HAM-D) Total Score at 3-Month Follow-Up</title>
          <description>Hamilton Depression scale (HAM-D) at 3-month followup assessment, which measures severity of depression symptoms Total scores are displayed and represent summed scores on 17 individual items the scale, and scale range for total scores is 0 to 50.
Higher scores indicate higher/worse levels of depression.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="7.39"/>
                    <measurement group_id="O2" value="11.45" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLFB - Total Cigarettes Smoked Week Before Appointment (at Post-Treatment)</title>
        <description>Timeline Followback - Total number of cigarettes smoked the week before Post-Treatment visit</description>
        <time_frame>Week before Post-Treatment visit occurring at week 12, i.e. number of cigarettes smoked for the week prior to this week 12 visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>TLFB - Total Cigarettes Smoked Week Before Appointment (at Post-Treatment)</title>
          <description>Timeline Followback - Total number of cigarettes smoked the week before Post-Treatment visit</description>
          <units>Number of Cigarettes Smoked</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.31" spread="29.00"/>
                    <measurement group_id="O2" value="17.03" spread="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TLFB - Cigarettes Smoked Week Before 3-Month Follow-up</title>
        <description>Timeline followback - Number of cigarettes smoked the week before 3-month follow-up visit</description>
        <time_frame>3-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Integrated Treatment</title>
            <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
          </group>
          <group group_id="O2">
            <title>Varenicline</title>
            <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
          </group>
        </group_list>
        <measure>
          <title>TLFB - Cigarettes Smoked Week Before 3-Month Follow-up</title>
          <description>Timeline followback - Number of cigarettes smoked the week before 3-month follow-up visit</description>
          <units>Number of Cigarettes Smoked</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.92" spread="45.64"/>
                    <measurement group_id="O2" value="25.85" spread="44.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the entire duration of data collection (2009-2015).</time_frame>
      <desc>Participants were assessed at each visit for adverse events (which typically occurred weekly).</desc>
      <group_list>
        <group group_id="E1">
          <title>Integrated Treatment</title>
          <description>Prolonged Exposure + Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
Prolonged Exposure: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders</description>
        </group>
        <group group_id="E2">
          <title>Varenicline</title>
          <description>Varenicline + Medication Management Counseling
Varenicline: 1 mg tablets, orally, twice daily x 12 weeks
Medication Management Counseling: 15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization (unrelated)</sub_title>
                <description>Reason for hospitalization unknown, but noted as unrelated to study procedures (general medical issue)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken ankle + hospitalization</sub_title>
                <description>Broken ankle unrelated to study procedures that required hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cocaine relapse with no hospitalization</sub_title>
                <description>Cocaine relapse with no hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory issue</sub_title>
                <description>Hospitalizations secondary to respiratory conditions (pneumonia, COPD, flu) for reasons unrelated to study procedures</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization secondary to drug or alcohol relapse</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <description>Increased fatigue, increased/decreased appetite, dry mouth, diarrhea, etc</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PPA verified by CO/cotinine was only assessed at two time-points (post-treatment, and follow-up)
medication adherence for varenicline was measured using pill count by the study nurse</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edna Foa</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2157463327</phone>
      <email>foa@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

